ProSci

CD80 Detection Set (Risk Free)

Product Code:
 
PSI-RF16040
Product Group:
 
Antibody Detection Sets
Supplier:
 
ProSci
Host Type:
 
Mouse
Antibody Isotype:
 
IgG1, IgG2b
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
See Set Contents
Regulatory Status:
 
RUO
Target Species:
 
Human
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Flow Cytometry
  • Immunocytochemistry (ICC)
  • Immunofluorescence (IF)
  • Immunohistochemistry- Paraffin Embedded (IHC-P)
  • Western Blot (WB)
Shipping:
 
blue ice
Storage:
 
Antibodies can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
PSI-RF16040-1Set1Set£447.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Background:
CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2). ProSci's Risk-FreeTM antibodies are mouse monoclonal antibodies made to improve in vivo studies. Unlike antibodies developed using proteins made in yeast or bacteria, Risk-FreeTM antibodies are developed with antigens expressed in mammalian cell lines, giving the most native post-translational modifications to the protein. Validated for flow cytometry and ELISA Rigorously tested for the following applications: Immunoblot Immunohistochemistry Immunocytochemistry Immunofluorescence Multiple antibodies per target allowing the user to choose the best antibody for their application Available individually or as a set Risk-FreeTM means they are guaranteed to work for their approved applications
Background References:
  • Lane P. Regulation of T and B cell responses by modulating interactions between CD28/CTLA-4 and their ligands, CD80 and CD86. Ann NY Acad Sci 1997; 815:392-400.
  • Feucht J, Kayser S, Gorodezki D, et al. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget 2016; 7:76902-19.
Buffer:
PBS containing 0.02% sodium azide.
Concentration:
Antibody 1 mg/mL
Conjugate:
Unconjugated
Immunogen:
CD80 antibodies were raised against the extracellular domain of human CD80.
Physical State:
Liquid
Purification:
Antibodies are supplied as protein A purified IgG1 and IgG2b.
Set Contents:
CD80 Antibody [8G12], Cat. No. RF16041 (20 μg)

CD80 Antibody [10A1], Cat. No. RF16042 (20 μg)

CD80 Antibody [7A2], Cat. No. RF16043 (20 μg)

CD80 Antibody [11D1], Cat. No. RF16044 (20 μg)

CD80 Antibody [11C12], Cat. No. RF16045 (20 μg)

CD80 Antibody [12D9], Cat. No. RF16046 (20 μg)
User Note:
Optimal dilutions for each application to be determined by the researcher.

Documents

References

  1. Lane P. Regulation of T and B cell responses by modulating interactions between CD28/CTLA-4 and their ligands, CD80 and CD86. Ann NY Acad Sci 1997; 815:392-400.
  2. Feucht J, Kayser S, Gorodezki D, et al. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget 2016; 7:76902-19.